[EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUES FUSIONNÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
申请人:UCB BIOPHARMA SPRL
公开号:WO2015086527A1
公开(公告)日:2015-06-18
A series of substituted fused tricyclic imidazole derivatives, in particular dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4- c']dipyridine, dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine and tetrahydro-6H- cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
一系列替代的融合三环咪唑衍生物,特别是二氢-1H-吡喃[4',3':4,5]咪唑[1,2-a]吡啶,1,2,3,4-四氢咪唑[1,2-a:5,4-c']二吡啶,二氢-1H-吡喃[3',4':4,5]咪唑[1,2-a]吡啶和四氢-6H-环庚七[4,5]咪唑[1,2-a]吡啶,及其类似物,作为人类TNFα活性的有效调节剂,因此在治疗和/或预防各种人类疾病方面具有益处,包括自身免疫和炎症性疾病;神经学和神经退行性疾病;疼痛和伤害感知性疾病;心血管疾病;代谢性疾病;眼科疾病;以及肿瘤学疾病。